Vertex starts Phase III of CF triple combo

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) began a Phase III trial to evaluate a triple combination of VX-659, tezacaftor and Kalydeco ivacaftor in 100

Read the full 225 word article

User Sign In